<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>353</serviceExecutionTime><Drug id="67569"><DrugName>A2AR PAM program (oral, psoriasis/osteoarthritis), Addex</DrugName><DrugSynonyms><Name><Value>adenosine 2 receptor agonists (oral, psoriasis/osteoarthritis), Addex</Value></Name><Name><Value>A2AR PAM program (oral, psoriasis/osteoarthritis), Addex</Value></Name></DrugSynonyms><CompanyOriginator id="30059">Addex Therapeutics Ltd</CompanyOriginator><CompaniesSecondary><Company id="30059">Addex Therapeutics Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="30059" type="Company"><TargetEntity id="5000050378" type="organizationId">Addex Pharma SA</TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"></TargetEntity><TargetEntity id="D010003" type="MeSH"></TargetEntity><TargetEntity id="-478836143" type="omicsDisease"></TargetEntity><TargetEntity id="747" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="245">Osteoarthritis</Indication><Indication id="281">Psoriasis</Indication></IndicationsSecondary><ActionsPrimary><Action id="21">Adenosine A2 receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-29T10:12:47.000Z</LastModificationDate><ChangeDateLast>2013-06-03T00:00:00.000Z</ChangeDateLast><AddedDate>2010-08-04T10:32:07.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30059" linkType="Company"&gt;Addex Therapeutics&lt;/ulink&gt; (previously  Addex Pharmaceuticals) was investigating a series of positive allosteric modulators (PAM),  which activate  the adenosine 2A receptor (A2AR), for the potential oral treatment of inflammatory disease including psoriasis and osteoarthritis  [&lt;ulink linkID="1121195" linkType="Reference"&gt;1121195&lt;/ulink&gt;], [&lt;ulink linkID="1388012" linkType="Reference"&gt;1388012&lt;/ulink&gt;]. In July 2009, the program was in research [&lt;ulink linkID="1121195" linkType="Reference"&gt;1121195&lt;/ulink&gt;]. In March 2013, the program was still ongoing [&lt;ulink linkID="1388012" linkType="Reference"&gt;1388012&lt;/ulink&gt;].  However,  in May 2013, the program was discontinued following company restructuring  [&lt;ulink linkID="1432084" linkType="Reference"&gt;1432084&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By July 2009, the primary screening had been completed and  primary hits had been identified [&lt;ulink linkID="1121195" linkType="Reference"&gt;1121195&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30059">Addex Therapeutics Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-31T00:00:00.000Z</StatusDate><Source id="1432084" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30059">Addex Therapeutics Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-31T00:00:00.000Z</StatusDate><Source id="1432084" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30059">Addex Therapeutics Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-16T00:00:00.000Z</StatusDate><Source id="1121195" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30059">Addex Therapeutics Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-16T00:00:00.000Z</StatusDate><Source id="1121195" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00056"><Name>Adenosine A2 receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1432084" linkType="reference" linkID="1432084"&gt;1432084&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1079742">Viva Biotech</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30059">Addex Therapeutics Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="1">Drug - Discovery/Design</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="144218" title="Viva Biotech to provide discovery service to advance Addex Therapeutics' development of oral small molecule A2AR PAMs"></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>